Sign in Subscribe
Diseases

Travere Therapeutics Launches FSGS Awareness Campaign Amid FDA Approval Filing for Filspari

Strategic Insights

— 1 min read

In a bid to create a community anthem for those affected by focal segmental glomerulosclerosis (FSGS), Travere Therapeutics has partnered with Grammy-winning producer Brian Kennedy and singer-songwriter David Rush to create the "Feel So Good Song." Both artists have FSGS, a disorder that causes scarring of kidney tissue, and have been working with the company to raise awareness about the condition. The song and related campaign, "Play It Forward," aim to uplift and bring together the FSGS community, with Rush and Kennedy encouraging others to share their stories and experiences on social media.

Key Takeaways:

  • Travere Therapeutics has filed for FDA approval of Filspari in FSGS, with a ruling expected by mid-January 2026.
  • The "Play It Forward" awareness campaign, launched on FSGS Awareness Day (June 10), features the "Feel So Good Song" by David Rush and Brian Kennedy, as well as testimonial videos from both artists.
  • Destyn Fuller Hope, a filmmaker and individual living with FSGS, directed a short film documenting the creation of the song.
  • David Rush has discussed his personal experience with FSGS, stating that he spent around 180 days in a dialysis chair and 600 hours undergoing treatment in one year.
  • The "Play It Forward" campaign encourages individuals with FSGS to share their stories and experiences on social media, using the song as an anthem.
  • Travere Therapeutics' Chief Commercial Officer, Peter Heerma, has stated that the company is expanding its commercial team and building on existing infrastructure for Filspari in IgA nephropathy, which will support a fast launch if the drug is approved in FSGS.
  • Travere Therapeutics may be on track for the first FDA approval of an FSGS treatment, but competitor Amicus Therapeutics has acquired U.S. rights to Dimerix's phase 3 FSGS prospect DMX-200 for $30 million.

Statistics:

  • 180 days spent in a dialysis chair by David Rush in one year.
  • 600 hours spent undergoing treatment by David Rush in one year.
  • 1 year: the time frame during which David Rush spent in dialysis and treatment.
  • 10 June 10: FSGS Awareness Day when Travere Therapeutics launched the "Play It Forward" campaign.
  • 30 million: The amount Amicus Therapeutics acquired U.S. rights to Dimerix's phase 3 FSGS prospect DMX-200 for.
  • Mid-January 2026: The expected date of the FDA ruling on Travere Therapeutics' filing for Filspari in FSGS.

Sources:

  • Travere Therapeutics
  • Brian Kennedy
  • David Rush
  • Destyn Fuller Hope
  • Peter Heerma, Chief Commercial Officer of Travere Therapeutics
  • Amicus Therapeutics
  • Dimerix
  • FDA

Read more